We probably just checked-off another requirement of the Nasdaq Appeals Panel.
The reason I started to look at Kohlberg and Mubadala was to see what kind of connection either had to Pfizer. Were they being influenced to delay the business combination, in order to cause us to miss this Appeals Panel requirement?
Luckily, our management planned for such contingency, and successfully executed Plan B (if that is what it was). You have no idea, no appreciation of, just had many deadly tentacles that management must avoid, if Humanigen, Janssen, Novavax, and possibly Innovation, are going to snatch the tens of billions of annual revenue dollars out of the ill-deserving, bloated hands of the Favored Ones.